Showing results (11-20 of 38) with videos related to

Sort By:
Pageof 4
British Journal of Pharmacology|June 21, 2005
The effects of flavoxate hydrochloride on voltage-dependent L-type Ca2+ currents in human urinary bladderToshihisa Tomoda, Manami Aishima, Naruaki Takano, et al.
Molecular and Clinical Oncology|March 26, 2021
Paclitaxel and carboplatin chemotherapy after platinum-based chemotherapy and pembrolizumab for metastatic urothelial carcinomaNobuki Furubayashi, Yoshifumi Hori, Futoshi Morokuma, et al.
Journal of Clinical Medicine Research|June 4, 2020
Treating Japanese Patients With Pembrolizumab for Platinum-Refractory Advanced Urothelial Carcinoma in Real-World Clinical PracticeNobuki Furubayashi, Kentaro Kuroiwa, Noriaki Tokuda, et al.
Japanese Journal of Clinical Oncology|December 13, 2016
Predictive factors of late biochemical recurrence after radical prostatectomyTakahito Negishi, Kentarou Kuroiwa, Yoshifumi Hori, et al.
In Vivo (Athens, Greece)|August 19, 2021
Clinical Outcomes of Mixed Response to Pembrolizumab in Advanced Urothelial Carcinoma After Platinum-based ChemotherapyNobuki Furubayashi, Takahito Negishi, Naotaka Sakamoto, et al.
Cancer Chemotherapy and Pharmacology|May 23, 2019
Efficacy and safety of 4-weekly cabazitaxel for castration-resistant prostate cancer: a multi-institutional studyMasaki Shiota, Motonobu Nakamura, Akira Yokomizo, et al.
Translational Andrology and Urology|August 5, 2024
Efficacy of avelumab maintenance therapy for advanced urothelial carcinoma with histologic subtype and divergent differentiation: a multicenter retrospective study conducted by the Uro-Oncology Group in KyushuAkinori Minato, Nobuki Furubayashi, Toshihisa Tomoda, et al.
Anticancer Research|November 29, 2023
Organ-specific Tumor Response to Avelumab Maintenance Therapy for Advanced Urothelial Carcinoma: A Multicenter Retrospective StudyNobuki Furubayashi, Akinori Minato, Toshihisa Tomoda, et al.
Anticancer Research|January 2, 2020
Prognostic Impact of Prior Androgen Receptor Axis-targeting Agents in Cabazitaxel Chemotherapy After DocetaxelMasaki Shiota, Motonobu Nakamura, Akira Yokomizo, et al.
Anticancer Research|August 2, 2019
Therapeutic Outcome of >10 Cycles of Cabazitaxel for Castration-resistant Prostate Cancer: A Multi-institutional StudyMasaki Shiota, Motonobu Nakamura, Akira Yokomizo, et al.
Pageof 4